Tian Mengxing, Xu Huiting, Wang Hongbin, Wang Huifen, Dai Zhu, Ding Chenchen, Guo Huan, Jin Xin
Department of Clinical Nutrition, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430079, China.
Department of Abdominal Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430079, China.
Nutr Rev. 2025 May 1;83(5):797-808. doi: 10.1093/nutrit/nuae130.
Sarcopenia has been identified as a potential predictor of poor prognosis in various types of cancer. However, the impact of pretreatment sarcopenia and the reduction of skeletal muscle mass during treatment on survival outcomes of patients with cervical cancer is still not well understood.
This meta-analysis was conducted to investigate the impact of pretreatment sarcopenia and treatment-associated muscle loss on survival outcomes in patients with cervical cancer.
The PubMed, EMBASE, Web of Science, and Cochrane Library databases were searched for studies exploring the relationship between muscle loss and the prognosis of cervical cancer until January 1, 2023.
The hazard ratios (HRs) and 95% CIs for overall survival (OS) and progression-free survival (PFS) were extracted.
The data were analyzed using R software. The studies' quality was assessed using the Quality in Prognostic Studies tool. Twelve observational studies involving 1498 patients with cervical cancer were included in the analysis, with a prevalence of sarcopenia ranging from 24.8% to 57.5%. Sarcopenia was an independent predictor of poor OS (HR, 1.68; 95% CI, 1.28-2.21; P < .01) and PFS (HR, 1.53; 95% CI, 1.19-1.98; P < .01) in patients with cervical cancer. Additionally, the decrease in skeletal muscle during treatment was also significantly related to the OS (HR, 4.46; 95% CI, 2.87-6.94; P < .01) and PFS (HR, 2.89; 95% CI. 1.83-4.55; P < .01).
The prevalence of pretreatment sarcopenia was high among patients with cervical cancer. Pretreatment sarcopenia and skeletal muscle loss during treatment both negatively affected prognosis in cervical cancer.
肌肉减少症已被确定为各类癌症预后不良的潜在预测指标。然而，宫颈癌患者治疗前的肌肉减少症以及治疗期间骨骼肌质量的减少对其生存结局的影响仍未得到充分了解。
本荟萃分析旨在研究治疗前肌肉减少症和治疗相关的肌肉损失对宫颈癌患者生存结局的影响。
检索了PubMed、EMBASE、Web of Science和Cochrane图书馆数据库，以查找截至2023年1月1日探索肌肉损失与宫颈癌预后之间关系的研究。
提取总生存（OS）和无进展生存（PFS）的风险比（HR）及95%置信区间（CI）。
使用R软件进行数据分析。采用预后研究质量工具评估研究质量。分析纳入了12项涉及1498例宫颈癌患者的观察性研究，肌肉减少症的患病率在24.8%至57.5%之间。肌肉减少症是宫颈癌患者OS不良（HR，1.68；95%CI，1.28 - 2.21；P <.01）和PFS不良（HR，1.53；95%CI，1.19 - 1.98；P <.01）的独立预测因素。此外，治疗期间骨骼肌的减少也与OS（HR，4.46；95%CI，2.87 - 6.94；P <.01）和PFS（HR，2.89；95%CI，1.83 - 4.55；P <.01）显著相关。
宫颈癌患者中治疗前肌肉减少症的患病率较高。治疗前的肌肉减少症和治疗期间的骨骼肌损失均对宫颈癌的预后产生负面影响。
